View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
April 20, 2017

Ionis and Ribo partner to commercialise RNA-targeted therapeutics in China

Ionis Pharmaceuticals has entered a collaboration and licence agreement with Suzhou Ribo Life Science (Ribo) to develop and commercialise ribonucleic acid (RNA)-targeted therapeutics in China.

Ionis Pharmaceuticals has entered a collaboration and licence agreement with Suzhou Ribo Life Science (Ribo) to develop and commercialise ribonucleic acid (RNA)-targeted therapeutics in China.

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

RNA interference (RNAi) pathway is mediated by short double-stranded RNA oligonucleotides called ‘small interfering RNAs’ or ‘siRNAs’.

To date, scientists have tried this pathway to inhibit disease-causing proteins by using double-stranded siRNAsdrugs that require complex formulations.

Using its expertise in oligonucleotide chemistry and design, Ionis has discovered strategies for designing single-stranded oligonucleotides that act through the RNAi mechanism.

Under the agreement, Ionis has granted a licence to Ribo to commercialise two Ionis Generation 2+ anti-sense drugs in metabolic disease and cancer and an option to licence a third pre-specified Generation 2+ anti-sense drug in China.

Furthermore, Ribo will conduct a multi-year research and drug discovery programme to identify drugs that useIonis' ssRNAi technology.

"The need for new medicines in China is growing rapidly, especially for metabolic diseases and certain genetically defined cancers."

Ionis will receive an undisclosed up-front payment and equity in Riboand also retains the rights to develop and commercialise ssRNAi technology and all drugs outside China.

Ionis Pharmaceuticals drug discovery senior vice-president and oncology and rare diseases franchise leader Brett Monia said: “The need for new medicines in China is growing rapidly, especially for metabolic diseases and certain genetically defined cancers.

“Ribo is the ideal partner for us in China. Ribo has made excellent progress in its RNAi therapeutic programmes and we believe we will benefit from their drug development and regulatory expertise in China.

“We believe that our partnership with Ribo maximises the value of our drugs in this collaboration by leveraging the clinical data generated in China to support the overall global development plan for each drug.”

After the identification of a development candidate, Ribo will have the option to licence each drug by paying Ionis a fee.

Ribo will also be responsible for development and commercialisation of every drug it licences in China.

In addition, Ionis will be eligible to receive development, regulatory and commercial milestone payments along with royalties.

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology